A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer\'s disease. Study details include: The double-blind treatment duration will include a screening period of up to 42 days followed by 12 weeks of treatment at home. The study duration will be 4-5 months. There will be 4 in-clinic visits and 1 phone call.
Epistemonikos ID: 94b7ba2e14739585d7b366a5790b7948b0cef150
First added on: Feb 19, 2024